InClinica CEO to Speak at the 3rd International Congress on Clinical Trials for Medical Devices
James Nolan to address designing a clinical program for success
PHILADELPHIA (SEPTEMBER 8, 2017) – InClinica, Inc., a global, clinical CRO, announced that CEO James Nolan presented a special lecture titled “Design a Clinical Program for Success” at the Third International Congress on Clinical Trials for Medical Devices on Thursday, September 7 in Budapest, Hungary.
Nolan’s lecture addressed the state of global clinical device development and the key issues facing clinical trials. He also covered the approaches these device companies need to succeed in the industry.
“More than 5,000 medical device trials are currently recruiting patients,” said Nolan. “In an industry that’s becoming increasingly competitive, companies must put careful thought into reimbursement strategies, regulatory hurdles, pre-clinical evaluation capabilities, patient recruitment and choosing the right CRO.”
The International Congress on Clinical Trials for Medical Devices focuses on the latest developments and upcoming regulations on clinical trials in medical devices internationally. The event directly addresses selecting a clinical site and investigator, understanding the process for obtaining approval to conduct a clinical trial, and the new regulations for planning and executing trials. For more information, visit: http://ctmd2017.com/default.aspx
InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in Israel, Malaysia/Singapore., the U.K., and throughout Europe.